Skip to Main Content

The age of RNA interference drugs has arrived.

Alnylam Pharmaceuticals announced positive results Wednesday from a closely watched phase 3 clinical trial of patisiran, the company’s lead drug designed to treat a rare nerve disorder known as familial amyloid polyneuropathy (FAP.)

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED
  • Seems a very small market(10,000) as I read it. Won’t the cost to consumer be astronomical! Happy for victims of FAP however.

Comments are closed.